FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / A Survey of Clinical Usage of Non-steroidal Intra-Articular ...
Frontiers in veterinary science2020; 7; 579967; doi: 10.3389/fvets.2020.579967

A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners.

Abstract: There are several non-steroidal intra-articular therapeutics (NSIATs) available for use by equine practitioners for the treatment of performance-limiting joint-related pathology. Information is limited on perceived clinical efficacy, recommended treatment protocols, and associated complications. Our objective with this cross-sectional survey was to investigate the current clinical usage of NSIATs by equine practitioners. An electronic cross-sectional convenience survey inquiring about the use of steroidal and NSIATS (platelet-rich plasma, autologous conditioned serum, autologous protein solution, cellular therapies, and polyacrylamide hydrogel) was distributed internationally to equine practitioners. A total of 353 surveys were completed. NSIATs were used by 87.5% of the participants. Corticosteroids and hyaluronic acid remain the intra-articular therapeutic of choice among practitioners, followed by autologous conditioned serum, platelet-rich plasma and autologous conditioned protein. Polyacrylamide hydrogel was the least used. Practitioners were more likely to use NSIATs if their caseload was > 50% equine (P < 0.001), they treated more than 10 horses intra-articularly per month (P < 0.001), and horses treated were considered English sport horses (P = 0.02). Years in practice and practice location did not influence the use of NSIATs. One of the most common reasons why NSIATs were chosen was to treat acute articular pathologies. As survey limitations, answers to questions regarding clinical response and complication rates were based on subjective estimation and practitioners recall, not clinical records. In conclusion, corticosteroids remain the most widely used intra-articular therapeutic. Among the NSIATs, blood-based products are more commonly used by practitioners, followed by cellular and synthetic products. Equine practitioners frequently use NSIATs, choosing to treat acute joint pathology more than previously reported.
Copyright © 2020 Velloso Alvarez, Boone, Braim, Taintor, Caldwell, Wright and Wooldridge.
Get Full Text
Publication Date: 2020-10-22 PubMed ID: 33195592PubMed Central: PMC7642446DOI: 10.3389/fvets.2020.579967Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research paper analyzes the current usage of non-steroidal intra-articular therapeutics (NSIATs) by equine practitioners for treating joint-related issues in horses, by conducting an international survey. The results indicate that these types of medication are commonly used, but corticosteroids remain the most popular, followed by blood-based products.

Key Objectives and Methodology

  • The study intended to explore the use of non-steroidal intra-articular therapeutics (NSIATs) by equine practitioners. NSIATs are medications injected directly into a joint to reduce inflammation and pain related to joint diseases.
  • The researchers distributed an electronic survey to international equine practitioners. The survey asked questions relating to their use of NSIATs and steroidal treatments, including their choice of therapeutics, treatment protocols, and any complications experienced.
  • A total of 353 practitioners completed the survey, giving a broad base of data for analysis.

Main Findings

  • The majority of respondents (87.5%) reported that they used NSIATs in their clinical practice.
  • Despite the availability of NSIATs, corticosteroids and hyaluronic acid were the most commonly used theraputics. These were followed by autologous conditioned serum, platelet-rich plasma, and autologous conditioned protein. Polyacrylamide hydrogel was least used among practitioners.
  • The likelihood of NSIAT use was higher if the practitioners had more than 50% equine caseload, treated more than 10 horses with intra-articular therapeutics per month, and if the horses they treated were considered English sport horses.
  • The number of years in practice and the location of the practice did not significantly influence the use of NSIATs.
  • Acute articular pathologies were a common reason for choosing NSIATs for treatment.

Limitations and Conclusion

  • The study acknowledges the subjective nature of the responses as a limitation. The clinical responses and complication rates provided by the practitioners were based on their recollection and estimation rather than objective clinical records.
  • Regardless of the range of therapeutics, corticosteroids remain the most widely used treatment for joint pathologies in horses. Among the NSIATs, practitioners favored blood-based products, followed by cellular and synthetic products.
  • The study concluded that equine practitioners frequently use NSIATs and are increasingly choosing to treat acute joint pathology with these therapeutics more than it was previously assumed.

Cite This Article

APA
Velloso Alvarez A, Boone LH, Braim AP, Taintor JS, Caldwell F, Wright JC, Wooldridge AA. (2020). A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners. Front Vet Sci, 7, 579967. https://doi.org/10.3389/fvets.2020.579967

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 7
Pages: 579967

Researcher Affiliations

Velloso Alvarez, Ana
  • Department of Clinical Sciences, Auburn University, Auburn, AL, United States.
Boone, Lindsey H
  • Department of Clinical Sciences, Auburn University, Auburn, AL, United States.
Braim, Amy Poulin
  • Zoetis, Parsippany, NJ, United States.
Taintor, Jenifer S
  • Department of Clinical Sciences, Auburn University, Auburn, AL, United States.
Caldwell, Fred
  • Department of Clinical Sciences, Auburn University, Auburn, AL, United States.
Wright, James C
  • Department of Pathobiology, Auburn University, Auburn, AL, United States.
Wooldridge, Anne A
  • Department of Clinical Sciences, Auburn University, Auburn, AL, United States.

References

This article includes 32 references
  1. Rossdale PD, Hopes R, Digby NJ, Offord K. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec (1985) 116:66–9.
    doi: 10.1136/vr.116.3.66pubmed: 3976145google scholar: lookup
  2. Neundorf RH, Lowerison MB, Cruz AM, Thomason JJ, McEwen BJ, Hurtig MB. Determination of the prevalence and severity of metacarpophalangeal joint osteoarthritis in Thoroughbred racehorses via quantitative macroscopic evaluation. Am J Vet Res (2010) 71:1284–93.
    doi: 10.2460/ajvr.71.11.1284pubmed: 21034319google scholar: lookup
  3. Caron JP. Intra-articular injections for joint disease in horses. Vet Clin North Am Equine Pract (2005) 21:559–73.
    doi: 10.1016/j.cveq.2005.07.003pubmed: 16297721google scholar: lookup
  4. Ferris DJ, Frisbie DD, McIlwraith CW, Kawcak CE. Current joint therapy usage in equine practice: a survey of veterinarians 2009. Equine Vet J (2011) 43:530–5.
    doi: 10.1111/j.2042-3306.2010.00324.xpubmed: 21668486google scholar: lookup
  5. Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res (2007) 68:290–6.
    doi: 10.2460/ajvr.68.3.290pubmed: 17331019google scholar: lookup
  6. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. J Orthop Res (2009) 27:1675–80.
    doi: 10.1002/jor.20933pubmed: 19544397google scholar: lookup
  7. Bertone AL, Ishihara A, Zekas LJ, Wellman ML, Lewis KB, Schwarze RA. Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses. Am J Vet Res (2014) 75:141–51.
    doi: 10.2460/ajvr.75.2.141pubmed: 24471750google scholar: lookup
  8. Broeckx S, Zimmerman M, Crocetti S, Suls M, Marien T, Ferguson SJ. Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS ONE (2014) 9:e85917.
    doi: 10.1371/journal.pone.0085917pmc: PMC3896436pubmed: 24465787google scholar: lookup
  9. Monteiro SO, Bettencourt EV, Lepage OM. Biologic strategies for intra-articular treatment and cartilage repair. J Equ Vet Sci (2015) 35:175–90.
    doi: 10.1016/j.jevs.2015.01.006google scholar: lookup
  10. Bogers SH. Cell-based therapies for joint disease in veterinary medicine: what we have learned and what we need to know. Front Vet Sci (2018) 5:70.
    doi: 10.3389/fvets.2018.00070pmc: PMC5911772pubmed: 29713634google scholar: lookup
  11. Linardi RL, Dodson ME, Moss KL, King WJ, Ortved KF. The effect of autologous protein solution on the inflammatory cascade in stimulated equine chondrocytes. Front Vet Sci (2019) 6:64.
    doi: 10.3389/fvets.2019.00064pmc: PMC6414419pubmed: 30895181google scholar: lookup
  12. Wilson JM, McKenzie E, Duesterdieck-Zellmer K. International survey regarding the use of rehabilitation modalities in horses. Front Vet Sci (2018) 5:120.
    doi: 10.3389/fvets.2018.00120pmc: PMC6004390pubmed: 29942811google scholar: lookup
  13. Walmsley JP. Diagnosis and treatment of ligamentous and meniscal injuries in the equine stifle. Vet Clin North Am Equine Pract (2005) 21:651–72.
    doi: 10.1016/j.cveq.2005.08.003pubmed: 16297726google scholar: lookup
  14. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury. Vet Surg (2014) 43:255–65.
    doi: 10.1111/j.1532-950X.2014.12100.xpubmed: 24433318google scholar: lookup
  15. Weiss ARR, Lee O, Eggenhofer E, Geissler E, Korevaar SS, Soeder Y. Differential effects of heat-inactivated, secretome-deficient MSC and metabolically active MSC in sepsis and allogenic heart transplantation. Stem Cells (2020) 38:797–807.
    doi: 10.1002/stem.3165pubmed: 32101344google scholar: lookup
  16. Hegewald AA, Ringe J, Bartel J, Kruger I, Notter M, Barnewitz D. Hyaluronic acid and autologous synovial fluid induce chondrogenic differentiation of equine mesenchymal stem cells: a preliminary study. Tissue Cell (2004) 36:431–8.
    doi: 10.1016/j.tice.2004.07.003pubmed: 15533458google scholar: lookup
  17. Bohannon LK, Owens SD, Walker NJ, Carrade DD, Galuppo LD, Borjesson DL. The effects of therapeutic concentrations of gentamicin, amikacin and hyaluronic acid on cultured bone marrow-derived equine mesenchymal stem cells. Equine Vet J (2013) 45:732–6.
    doi: 10.1111/evj.12045pubmed: 23448189google scholar: lookup
  18. Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods (2009) 15:431–5.
    doi: 10.1089/ten.tec.2008.0534pmc: PMC2819709pubmed: 19216642google scholar: lookup
  19. Goodrich LR, Chen AC, Werpy NM, Williams AA, Kisiday JD, Su AW. Addition of mesenchymal stem cells to autologous platelet-enhanced fibrin scaffolds in chondral defects: does it enhance repair?. J Bone Jt Surg (2016) 98:23–34.
    doi: 10.2106/JBJS.O.00407pmc: PMC4697360pubmed: 26738900google scholar: lookup
  20. Edmonds RE, Garvican ER, Smith RK, Dudhia J. Influence of commonly used pharmaceutical agents on equine bone marrow-derived mesenchymal stem cell viability. Equine Vet J (2017) 49:352–7.
    doi: 10.1111/evj.12590pubmed: 27160051google scholar: lookup
  21. Parker RA, Clegg PD, Taylor SE. The in vitro effects of antibiotics on cell viability and gene expression of equine bone marrow-derived mesenchymal stromal cells. Equine Vet J (2012) 44:355–60.
    doi: 10.1111/j.2042-3306.2011.00437.xpubmed: 21883415google scholar: lookup
  22. Pezzanite L, Chow L, Soontararak S, Phillips J, Goodrich L, Dow S. Amikacin induces rapid dose-dependent apoptotic cell death in equine chondrocytes and synovial cells in vitro. Equ Vet J (2020) 52:715–24.
    doi: 10.1111/evj.13243pubmed: 31997397google scholar: lookup
  23. Rinnovati R, Romagnoli N, Gentilini F, Lambertini C, Spadari A. The influence of environmental variables on platelet concentration in horse platelet-rich plasma. Acta Vet Scand (2016) 58:45.
    doi: 10.1186/s13028-016-0226-3pmc: PMC4932754pubmed: 27377748google scholar: lookup
  24. Sutter WW, Kaneps AJ, Bertone AL. Comparison of hematologic values and transforming growth factor-beta and insulin-like growth factor concentrations in platelet concentrates obtained by use of buffy coat and apheresis methods from equine blood. Am J Vet Res (2004) 65:924–30.
    doi: 10.2460/ajvr.2004.65.924pubmed: 15281650google scholar: lookup
  25. Giraldo CE, Lopez C, Alvarez ME, Samudio IJ, Prades M, Carmona JU. Effects of the breed, sex and age on cellular content and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel. BMC Vet Res (2013) 9:29.
    doi: 10.1186/1746-6148-9-29pmc: PMC3577464pubmed: 23402541google scholar: lookup
  26. Burkett BN, Thomason JM, Hurdle HM, Wills RW, Fontenot RL. Effects of firocoxib, flunixin meglumine, and phenylbutazone on platelet function and thromboxane synthesis in healthy horses. Vet Surg (2016) 45:1087–94.
    doi: 10.1111/vsu.12567pubmed: 27731498google scholar: lookup
  27. Marohl T, Rothenbuhler R, Leach M, King W, Woodell-May J. Cox-inhibitors do not impact anti-inflammatory IL-1ra concentrations in autologous protein solution. In: International Cartilage Repair Society. (2016).
  28. Marohl T, Rothenbuhler R, Leach M, King W, Woodell-May J. Steroids methylprednisolone and triamcinolone do not impact anti-inflammatory IL-1ra concentrations in autologous protein solution. In: International Cartilage Repair Society (2016).
  29. Muller M, Raabe O, Addicks K, Wenisch S, Arnhold S. Effects of non-steroidal anti-inflammatory drugs on proliferation, differentiation and migration in equine mesenchymal stem cells. Cell Biol Int (2011) 35:235–48.
    doi: 10.1042/CBI20090211pubmed: 21087205google scholar: lookup
  30. Gilbertie JM, Davis JL, Davidson GS, McDonald AM, Schirmer JM, Schnabel LV. Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. Equine Vet J (2019) 51:537–43.
    doi: 10.1111/evj.13048pubmed: 30465727google scholar: lookup
  31. Tnibar A, Persson A, Nielsen H, Svalastoga E, Westrup U, McEvoy F. Evaluation of a polyacrylamide hydrogel in the treatment of induced osteoarthritis in a goat model: a randomized controlled pilot study. Osteoarthr Cartil (2014) 22:S477.
    doi: 10.1016/j.joca.2014.02.906google scholar: lookup
  32. Tnibar A, Schougaard H, Camitz L, Rasmussen J, Koene M, Jahn W. An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up. Acta Vet Scand (2015) 57:20.
    doi: 10.1186/s13028-015-0110-6pmc: PMC4403890pubmed: 25887429google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.